Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity lowers target price on Kitwave

(Sharecast News) - Analysts at Canaccord Genuity lowered their target price on Kitwave from 495.0p to 420.0p on Tuesday, noting that the firm's "tough start" to H2 had prompted FY25 forecast revisions. Canaccord Genuity said Kitwave's H1 results showed "further progress", with revenues advancing both organically and via recent acquisitions, while adjusted underlying earnings rose 22% to £13.2m, in line with internal expectations.

However, a combination of recent softer trading due to weaker consumer confidence and the macro impact of NIC increases on the Group's customers, continued investment into the South West to support the depot transition and the direct impact of NIC increases, which management no longer believes it can offset, unfortunately results in a lowering of FY25 profit expectations.

The Canadian bank updated its FY25 profit forecasts in line with management guidance, with adjusted EBIT reducing by 14% to £38.1m, at the low end of its £38.0m-40.5m guidance range, while outer year reductions were "more modest" at 8% and 6% in FY26 and FY27, respectively.

"Whilst today's news is clearly disappointing, especially in the context of KITW's strong track record of delivery and outperformance post IPO, we believe the medium-term growth opportunities remain undiminished," said Canaccord. "Balance sheet strength remains and recent acquisition integrations are progressing well and provide KITW with the building blocks and national footprint for further profitable growth in what remains a largely fragmented wholesale market."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.